---
figid: PMC9618820__fphar-13-1031527-g001
pmcid: PMC9618820
image_filename: fphar-13-1031527-g001.jpg
figure_link: /pmc/articles/PMC9618820/figure/F1/
number: FIGURE 1
figure_title: ''
caption: Mechanisms of CTLA-4. DCs activate T cells via B7-CD28, while CTLA-4 can
  bind with B7 on Tregs and cancer cells with higher affinity, and Tregs can inversely
  inhibit DCs via B7-CTLA-4. Therefore, CTLA-4 inhibitors may block this pathway to
  restore the activation of T cells.
article_title: 'Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging
  future.'
citation: Zeng Zhang, et al. Front Pharmacol. 2022;13:1031527.
year: '2022'

doi: 10.3389/fphar.2022.1031527
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.

keywords:
- osteosarcoma
- immunotherapy
- immune checkpoint inhibitor
- side effects
- mechanism

---
